Related Experiment Videos
Solution behavior of a novel type 1 interferon, interferon-tau
Derrick S Katayama1, Rajiv Nayar, Danny K Chou
1Center for Pharmaceutical Biotechnology, University of Colorado Health Sciences Center, Denver, Colorado, USA.
Journal of Pharmaceutical Sciences
|November 1, 2005
Summary
Interferon-tau (IFN-tau) protein remains stable and monomeric at high concentrations and across a wide pH range. This cytokine can be formulated into low-water capsules, suggesting therapeutic potential.
Area of Science:
- Biochemistry
- Protein Chemistry
- Immunology
Background:
- Interferon-tau (IFN-tau) is a novel cytokine identified during mammalian fetal development.
- IFN-tau is under investigation for potential therapeutic applications in viral infections and autoimmune diseases.
- Developing a stable formulation is crucial for the commercialization of IFN-tau.
Purpose of the Study:
- To characterize the solution behavior of Interferon-tau (IFN-tau).
- To assess the structural stability of IFN-tau under various conditions.
- To determine the feasibility of formulating IFN-tau for therapeutic use.
Main Methods:
- Utilized various biophysical methods to study IFN-tau's solution behavior.
- Investigated protein structure, stability, and aggregation.
- Assessed structural integrity across different pH ranges and solvent conditions.
Main Results:
- IFN-tau exhibits a well-defined four-helix bundle structure, typical of type 1 interferons.
- The protein's globular structure has a free energy of unfolding of approximately 4 kcal/mole at room temperature.
- IFN-tau remains monomeric up to 60 mg/mL and maintains structural integrity between pH 2-8.
- While non-aqueous solvents alter the structure, IFN-tau refolds efficiently upon dilution in aqueous media.
Conclusions:
- IFN-tau demonstrates significant structural stability across a broad pH range and remains monomeric at high concentrations.
- The ability of IFN-tau to refold after exposure to non-aqueous solvents facilitates its formulation in low water content systems.
- These findings support the development of IFN-tau formulations, such as capsules, for therapeutic applications.